SANOFI3,109.80

Sanofi India Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersSENORESINNOVACAPPGHLMOREPENLABIOLCPSANOFICONRFDCORCHPHARMAMcap ₹7,153 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q1 FY24
30/06/2023
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Revenue from Operations706.1714.6693.9732.4463.5524.0514.9
Other Income15.711.812.06.54.82.35.9
Total Income721.8726.4705.9738.9468.3526.3520.8
Expenses
+ Cost of Materials Consumed154.4131.0133.5143.782.193.1102.7
+ Purchases of Stock-in-Trade188.5395.2134.640.892.5201.8238.5
+ Changes in Inventories-26.6-226.412.2123.946.5-34.9-91.4
+ Employee Benefit Expense93.793.191.992.460.256.753.8
+ Finance Costs0.70.30.40.30.40.40.4
+ Depreciation & Amortisation9.89.910.210.09.09.09.6
+ Other Expenses117.9113.4134.3112.766.587.693.0
Total Expenses538.4516.5517.1523.8357.2413.7406.6
EBITDA178.2208.3187.4218.9115.7119.7118.3
EBIT168.4198.4177.2208.9106.7110.7108.7
Profit
PBT before Exceptional Items183.4209.9188.8215.1111.1112.6114.2
+ Exceptional Items0.00.00.0-26.7-19.00.08.0
Pretax Income183.4209.9188.8188.492.1112.6122.2
+ Current Tax61.358.649.660.027.231.027.9
+ Deferred Tax-0.8-0.71.5-8.2-3.3-0.63.0
Tax Expense60.557.951.151.823.930.430.9
Net Income122.9151.9137.7136.6103.282.291.3
+ Net Income — Continuing Ops122.9151.9137.7136.668.282.291.3
+ Net Income — Discontinued Ops0.00.00.00.035.00.00.0
+ Other Comprehensive Income0.00.0-1.30.00.00.07.2
Total Comprehensive Income122.9151.9136.4136.6103.282.298.5
Per Share
Basic EPS53.3765.9559.7959.3144.8135.6939.64
Diluted EPS53.3765.9559.7959.3144.8135.6939.60
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax0.00.00.00.047.10.00.0
+ Tax — Discontinued Operations0.00.00.00.012.10.00.0
Other Comprehensive Income — detail
+ Items NOT to be Reclassified to P&L-1.8
+ Tax on Items NOT to be Reclassified — alt tag-0.5-9.6
+ Tax on Items to be Reclassified — alt tag2.4
Per Share — as-filed variants
Basic EPS — Continuing Operations53.3765.9559.7959.3129.6235.6939.64
Diluted EPS — Continuing Operations53.3765.9559.7959.3129.6235.6939.60
Basic EPS — Discontinued Operations0.000.000.000.0015.190.000.00
Diluted EPS — Discontinued Operations0.000.000.000.0015.190.000.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit389.8414.8413.6424.0242.4264.0265.1
Gross Margin %55.2058.0559.6157.8952.3050.3951.49
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)183.4209.9188.8215.1111.1112.6114.2
− Exceptional Items (reconciliation)0.00.00.0-26.7-19.00.08.0
Net Income Adj (tax-effected)122.9151.9137.7156.0117.382.285.3
EPS Adj53.3765.9559.7967.7250.9235.6937.04
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.00
Paid Up Equity Capital23.023.023.023.023.023.023.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q3 FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.